Oral Medications
-

Novo Nordisk Boosts Oral GLP-1 Production Amid Intensifying Competition
Novo Nordisk commits €432 million to scale oral GLP-1 production in Ireland, solidifying its chronic disease treatment focus.

Novo Nordisk commits €432 million to scale oral GLP-1 production in Ireland, solidifying its chronic disease treatment focus.